Loading clinical trials...
Loading clinical trials...
A Phase 2 Study of Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary Central Nervous System Lymphoma
Conditions
Interventions
Methotrexate
Rituximab (where available)
+1 more
Locations
8
Canada
Arthur J.E. Child Comprehensive Cancer Centre
Calgary, Alberta, Canada
BCCA - Vancouver
Vancouver, British Columbia, Canada
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, Canada
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
University Health Network
Toronto, Ontario, Canada
The Research Institute of the McGill University
Montreal, Quebec, Canada
Start Date
February 13, 2024
Primary Completion Date
May 31, 2028
Completion Date
December 31, 2028
Last Updated
April 14, 2026
NCT07249528
NCT06090539
NCT05272384
NCT07523555
NCT07260812
NCT06189391
Lead Sponsor
Canadian Cancer Trials Group
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions